Core Viewpoint - The company emphasizes the importance of strategic partnerships and is actively seeking diverse collaboration opportunities with leading global biopharmaceutical firms, promising to disclose any significant developments in a timely manner [1] Group 1 - The company is focused on strategic cooperation and is engaging with top global biopharmaceutical companies [1] - The company is exploring various collaboration methods to enhance its strategic partnerships [1] - The company commits to timely announcements regarding any major progress in its partnerships [1]

Core Viewpoint - The company emphasizes its commitment to legal compliance and timely information disclosure in response to investor inquiries [1] Group 1 - The company stated that it adheres to laws, regulations, and exchange rules regarding information disclosure [1] - The establishment of wholly-owned subsidiaries is considered a routine business operation and does not fall under mandatory disclosure requirements [1]

Group 1 - The company, BeiGene, submitted an application for the issuance of overseas listed shares (H shares) and for listing on the Hong Kong Stock Exchange on September 29, 2025 [2] - The application materials for this issuance and listing were published on the Hong Kong Stock Exchange's website on the same day [2] - The related work for the Hong Kong stock listing is progressing in an orderly manner, and the company will announce any significant developments in a timely manner [2]

Group 1 - The core concern raised by investors is about the potential delay in the listing of MCLA-129, suggesting that if it is not submitted soon, the competitive landscape may diminish significantly [2] - Beida Pharmaceutical (300558.SZ) has responded that the clinical trial work for MCLA-129 is progressing in an orderly manner and that the company will announce any significant developments in a timely manner [2]

Group 1 - The company has scheduled the disclosure date for its 2025 annual report on April 23, 2026, which is later than many peers [2] - The company responded to investor concerns regarding the late reporting date, indicating that it is due to the progress of business operations [2] - The company assures that its operations are normal and advises stakeholders to refer to official disclosures for performance-related information [2]

免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 董秘回答(贝达药业SZ300558)： 您好！目前MCLA-129的临床试验工作正在有序推进中，如有重大进展公司会及时公告披露。谢谢！查 看更多董秘问答>> 投资者提问： 129再不申报上市，就不用申报了，马上竞争局势连汤都不剩了？ ...

投资者提问： 您好！公司已按工作业务的相关进展预约2026年4月23日为2025年年度报告披露日。目前公司经营正 常，2025年业绩相关信息请以公司公开披露为准。谢谢！查看更多董秘问答>> 为什么年报时间这么晚，几乎就是最后几个，是不是业绩亏损？为什么不直接4.30日披露？ 董秘回答(贝达药业SZ300558)： 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 ...

Core Viewpoint - The company has completed the equity transfer with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical, which specializes in high-end inhalation formulations [1] Group 1: Investment Details - The company invested 50 million yuan to acquire the 2 million yuan registered capital of Zhixing Pharmaceutical [1] - The post-investment ownership in Zhixing Pharmaceutical is 20% [1] Group 2: Company and Product Focus - Zhixing Pharmaceutical focuses on the development of high-end inhalation formulations, with a strong background in core technical personnel and a well-established R&D and production system [1] - Inhalation formulations are defined as drug delivery systems that utilize inhalation devices to administer medication to the respiratory tract, offering local or systemic therapeutic effects [1] Group 3: Market Potential and Applications - Inhalation formulations are recommended by domestic and international guidelines as the preferred treatment for asthma and chronic obstructive pulmonary disease (COPD) [1] - The technology is expanding into other fields, including vaccines and central nervous system applications, and offers new exploration directions for lung cancer treatment due to its targeted delivery and flexibility [1] - The company's investment aligns with its long-term strategic development in the high-end inhalation formulation sector, fostering deep collaboration in innovation and technology platforms [1]

Investment Rating - The investment rating for the company is "Buy-A" with a 12-month target price of 71.95 CNY per share [4]. Core Insights - The report highlights that the company is entering a significant growth phase with multiple new products in the domestic market and the overseas market poised for key data readouts, particularly for the long-acting eye drug EYP-1901 [1][2][3]. Summary by Sections Overseas Market - EYP-1901, a long-acting eye drug, is expected to read out phase 3 clinical data for wet age-related macular degeneration (wAMD) by mid-2026, which could catalyze significant market potential [2][24]. - The competitive landscape for VEGF small molecule eye drugs is favorable, with EYP-1901 leading in development progress [2][30]. - EYP-1901 offers a differentiated advantage with a dosing frequency of once every six months, which is expected to significantly improve patient adherence compared to current treatments like Aflibercept, which requires dosing every two months [2][34]. Domestic Market - The company has several new products entering a rapid growth phase, including plant-derived recombinant albumin and long-acting factor VIII, which are expected to capture significant market share [3][21]. - The sales of Enasidenib and Bevacizumab are accelerating, indicating strong growth potential in the lung cancer and other oncology markets [3][21]. - Revenue projections for the company are optimistic, with expected revenues of 3.55 billion CNY, 4.46 billion CNY, and 5.48 billion CNY for 2025, 2026, and 2027 respectively, alongside net profits of 409 million CNY, 704 million CNY, and 896 million CNY for the same years [3][8]. Financial Forecast - The company is projected to achieve a revenue growth rate of approximately 15.9% year-on-year for the first three quarters of 2025, driven by the launch of multiple new drugs [17][21]. - The earnings per share (EPS) are expected to increase from 0.97 CNY in 2025 to 2.13 CNY in 2027, reflecting a strong growth trajectory [8][21].

Core Viewpoint - Beida Pharmaceutical has completed a share transfer agreement with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical for 50 million yuan, aiming to enhance its position in the biopharmaceutical sector and strengthen its ecosystem in high-barrier technology areas [1] Group 1 - Beida Pharmaceutical's investment in Hangzhou Zhixing Pharmaceutical is part of its strategy to leverage its advantages in the biopharmaceutical field [1] - The company aims to continuously improve its ecosystem layout around high-barrier technology [1] - The acquisition involves a total registered capital of 200 million yuan for Zhixing Pharmaceutical, indicating a significant commitment to the partnership [1] Group 2 - Hangzhou Zhixing Pharmaceutical specializes in the development of high-end inhalation formulations [1] - The core technical team of Zhixing Pharmaceutical has a strong industry background, which is crucial for its operations [1] - Zhixing Pharmaceutical has established a comprehensive research and production system, demonstrating its capability to transition products from laboratory to industrialization [1]